Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22206346 | 1.00 | GPR139 (0.35) | GPR139RETPDE3BPDE3AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL22206396 | 0.94 | GPR139 (0.34) | GPR139RET | |
| SCHEMBL22092265 | 0.88 | GPR139 (0.34) | GPR139 | |
| SCHEMBL22206390 | 0.86 | GRM5 (0.45) | GPR139 | |
| Trifluoroacetic Acid SCHEMBL22206380 | 0.84 | GPR139 (0.33) | GPR139 | |
| SCHEMBL22206347 | 0.82 | GPR139 (0.34) | GPR139ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL22092065 | 0.81 | GRM5 (0.42) | GPR139 | |
| SCHEMBL22092071 | 0.78 | GPR139 (0.40) | GPR139 | |
| Trifluoroacetic Acid SCHEMBL22206367 | 0.78 | GPR139 (0.33) | GPR139 | |
| SCHEMBL22092121 | 0.78 | GPR139 (0.34) | GPR139PDE3BPDE3AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | VAPB, HDLBP, VAPA | GPR139 4033/4885RET 1707/4885PDE3B 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.